FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220867282> ?p ?o ?g. }

• W4220867282 endingPage "129" @default.
• W4220867282 startingPage "117" @default.
• W4220867282 abstract "Whether hepatitis C virus (HCV) infection is associated with breast cancer risk remains elusive, and we aimed to elucidate it. A nationwide population-based cohort study of the Taiwan National Health Insurance Research Database (TNHIRD) was conducted. Additionally, breast cancer risk factors, and HCV core expression were surveyed in breast cancer patients of a tertiary care center. Three TNHIRD cohorts (1:4:4, propensity score-matched, 2003–2012), including HCV-treated (3646 HCV-infected females with interferon-based therapy ≥6 months), HCV-untreated (n = 14,584) and HCV-uninfected (n = 14,584) cohorts, were enrolled. The HCV-untreated cohort had the highest 9-year breast cancer cumulative incidence (2.017%; 95% confidence interval [CI]: 1.382%–2.846%), while the HCV-treated (1.073%; 0.414%–2.356%), and HCV-uninfected (1.453%; 0.785%–2.486%) cohorts showed no difference. Untreated HCV infection (hazard ratio [HR]: 1.701; 95% CI: 1.205%–2.400), urban residency (1.658, 1.183–2.323), and baseline cardiovascular events (1.920; 1.005–3.668) were associated with incident breast cancers. The interaction analysis showed that particularly among patients <49 years, HCV infection was associated with breast cancer development (2.193; 1.097–4.384). Of 12,170 hospitalized breast cancer patients, 4.90% were HCV Ab-positive. HCV Ab-positive patients were older (60.92+/-10.82 vs 53.91+/-11.38 years, P < 0.0001) and had a higher body mass index (25.39+/-5.1 vs 24.5+/-4.3 kg/m2, P = 0.007), rates of diabetes (30.60 vs 19.98%, P < 0.0001), hypertension (46.9 vs 30.39%, P < 0.0001), dyslipidemia (25.52 vs 20.28%, P = 0.031), and hyperuricemia (11.38 vs 5.52%, P < 0.0001) than their counterparts. No HCV core-positive cells were demonstrated in breast cancer tissues. Conclusions: Untreated HCV infection, urbanization, and cardiovascular events were potential risk factors for breast cancer. The HCV-associated risk was most prominent among patients <49 years, might not be associated with in situ HCV core-related oncogenesis but with metabolic alterations, and was reversed by anti–HCV therapy. Whether hepatitis C virus (HCV) infection is associated with breast cancer risk remains elusive, and we aimed to elucidate it. A nationwide population-based cohort study of the Taiwan National Health Insurance Research Database (TNHIRD) was conducted. Additionally, breast cancer risk factors, and HCV core expression were surveyed in breast cancer patients of a tertiary care center. Three TNHIRD cohorts (1:4:4, propensity score-matched, 2003–2012), including HCV-treated (3646 HCV-infected females with interferon-based therapy ≥6 months), HCV-untreated (n = 14,584) and HCV-uninfected (n = 14,584) cohorts, were enrolled. The HCV-untreated cohort had the highest 9-year breast cancer cumulative incidence (2.017%; 95% confidence interval [CI]: 1.382%–2.846%), while the HCV-treated (1.073%; 0.414%–2.356%), and HCV-uninfected (1.453%; 0.785%–2.486%) cohorts showed no difference. Untreated HCV infection (hazard ratio [HR]: 1.701; 95% CI: 1.205%–2.400), urban residency (1.658, 1.183–2.323), and baseline cardiovascular events (1.920; 1.005–3.668) were associated with incident breast cancers. The interaction analysis showed that particularly among patients <49 years, HCV infection was associated with breast cancer development (2.193; 1.097–4.384). Of 12,170 hospitalized breast cancer patients, 4.90% were HCV Ab-positive. HCV Ab-positive patients were older (60.92+/-10.82 vs 53.91+/-11.38 years, P < 0.0001) and had a higher body mass index (25.39+/-5.1 vs 24.5+/-4.3 kg/m2, P = 0.007), rates of diabetes (30.60 vs 19.98%, P < 0.0001), hypertension (46.9 vs 30.39%, P < 0.0001), dyslipidemia (25.52 vs 20.28%, P = 0.031), and hyperuricemia (11.38 vs 5.52%, P < 0.0001) than their counterparts. No HCV core-positive cells were demonstrated in breast cancer tissues. Conclusions: Untreated HCV infection, urbanization, and cardiovascular events were potential risk factors for breast cancer. The HCV-associated risk was most prominent among patients <49 years, might not be associated with in situ HCV core-related oncogenesis but with metabolic alterations, and was reversed by anti–HCV therapy." @default.
• W4220867282 created "2022-04-03" @default.
• W4220867282 creator A5001390997 @default.
• W4220867282 creator A5033503884 @default.
• W4220867282 creator A5043780319 @default.
• W4220867282 creator A5045522098 @default.
• W4220867282 creator A5046215886 @default.
• W4220867282 creator A5057620530 @default.
• W4220867282 creator A5075284638 @default.
• W4220867282 creator A5087803209 @default.
• W4220867282 date "2022-07-01" @default.
• W4220867282 modified "2023-10-16" @default.
• W4220867282 title "Association between breast cancer and hepatitis C: A joint study of hospitalized patients and nationwide cohorts" @default.
• W4220867282 cites W1963813168 @default.
• W4220867282 cites W1977300462 @default.
• W4220867282 cites W1981036435 @default.
• W4220867282 cites W1994597779 @default.
• W4220867282 cites W1998469837 @default.
• W4220867282 cites W1998939734 @default.
• W4220867282 cites W2007113606 @default.
• W4220867282 cites W2010317967 @default.
• W4220867282 cites W2035242291 @default.
• W4220867282 cites W2038981426 @default.
• W4220867282 cites W2040246440 @default.
• W4220867282 cites W2046834033 @default.
• W4220867282 cites W2051759477 @default.
• W4220867282 cites W2053978445 @default.
• W4220867282 cites W2058582559 @default.
• W4220867282 cites W2071988456 @default.
• W4220867282 cites W2079278825 @default.
• W4220867282 cites W2081482855 @default.
• W4220867282 cites W2116836111 @default.
• W4220867282 cites W2129168200 @default.
• W4220867282 cites W2130453232 @default.
• W4220867282 cites W2138958819 @default.
• W4220867282 cites W2139773897 @default.
• W4220867282 cites W2143945693 @default.
• W4220867282 cites W2146392601 @default.
• W4220867282 cites W2147314679 @default.
• W4220867282 cites W2153720399 @default.
• W4220867282 cites W2154189955 @default.
• W4220867282 cites W2166277656 @default.
• W4220867282 cites W2313055161 @default.
• W4220867282 cites W2339375057 @default.
• W4220867282 cites W2397550578 @default.
• W4220867282 cites W2417150610 @default.
• W4220867282 cites W2460113260 @default.
• W4220867282 cites W2507802024 @default.
• W4220867282 cites W2578013986 @default.
• W4220867282 cites W2588578122 @default.
• W4220867282 cites W2735035726 @default.
• W4220867282 cites W2735968982 @default.
• W4220867282 cites W2776465982 @default.
• W4220867282 cites W2788177308 @default.
• W4220867282 cites W2791775476 @default.
• W4220867282 cites W2845328011 @default.
• W4220867282 cites W2885738414 @default.
• W4220867282 cites W2886144553 @default.
• W4220867282 cites W2886169009 @default.
• W4220867282 cites W2888197850 @default.
• W4220867282 cites W2991564522 @default.
• W4220867282 cites W3173290212 @default.
• W4220867282 doi "https://doi.org/10.1016/j.trsl.2022.02.009" @default.
• W4220867282 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35259528" @default.
• W4220867282 hasPublicationYear "2022" @default.
• W4220867282 type Work @default.
• W4220867282 citedByCount "3" @default.
• W4220867282 countsByYear W42208672822023 @default.
• W4220867282 crossrefType "journal-article" @default.
• W4220867282 hasAuthorship W4220867282A5001390997 @default.
• W4220867282 hasAuthorship W4220867282A5033503884 @default.
• W4220867282 hasAuthorship W4220867282A5043780319 @default.
• W4220867282 hasAuthorship W4220867282A5045522098 @default.
• W4220867282 hasAuthorship W4220867282A5046215886 @default.
• W4220867282 hasAuthorship W4220867282A5057620530 @default.
• W4220867282 hasAuthorship W4220867282A5075284638 @default.
• W4220867282 hasAuthorship W4220867282A5087803209 @default.
• W4220867282 hasConcept C120665830 @default.
• W4220867282 hasConcept C121332964 @default.
• W4220867282 hasConcept C121608353 @default.
• W4220867282 hasConcept C126322002 @default.
• W4220867282 hasConcept C143998085 @default.
• W4220867282 hasConcept C201903717 @default.
• W4220867282 hasConcept C203014093 @default.
• W4220867282 hasConcept C207103383 @default.
• W4220867282 hasConcept C2522874641 @default.
• W4220867282 hasConcept C2776408679 @default.
• W4220867282 hasConcept C2776455275 @default.
• W4220867282 hasConcept C2778527826 @default.
• W4220867282 hasConcept C2908647359 @default.
• W4220867282 hasConcept C44249647 @default.
• W4220867282 hasConcept C530470458 @default.
• W4220867282 hasConcept C61511704 @default.
• W4220867282 hasConcept C71924100 @default.
• W4220867282 hasConcept C72563966 @default.
• W4220867282 hasConcept C88879693 @default.
• W4220867282 hasConcept C99454951 @default.
• W4220867282 hasConceptScore W4220867282C120665830 @default.

• next